Close Menu

Bio-Rad

Bio-Rad reported $570.6 million in revenues in Q4, a 5 percent drop year over year but a 3 percent increase on a currency-neutral basis.

The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.

The firms will develop a workflow for single cell genomic analysis using a modified version of Bio-Rad's droplet generator instrument.

The firms will develop a cost-effective, scalable solution that incorporates Bio-Rad's droplet partitioning technology with Illumina's NGS and BaseSpace data analysis.

Bio-Rad brought a claim before the American Arbitration Association in 2014, alleging that three 10X Genomics founders breached certain contractual obligations.

The UCSF-based Blood Systems Research Institute will conduct research using RainDance's digital PCR platforms as part of a new $20 million amfAR Institute for HIV Cure Research.

The ratings company cited Bio-Rad's historically low leverage and low debt load, which provides a cushion against the costs associated with internal projects.

The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.

Sales were down in both the Life Sciences and Clinical Diagnostics segments, but the firm reported an increase in net income compared to the year-ago period. 

Posters described Droplet Digital PCR for oncology, somatic mosaicism detection, and gene editing methods development.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.